Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Practical Acute Myeloid Leukemia (AML) Biomarker Testing Using Next-Generation Sequencing (NGS) Technology: A Comprehensive, Rapid, Inexpensive and Flexible Approach

Rebecca F McClure, MD, Tyler Kirwan, Zachary Castonguay, Amanda Marolt, Michael Rutherford, MD

Blood (2015) 126 (23): 4973.

https://doi.org/10.1182/blood.V126.23.4973.4973

Published: 2015

Journal Articles

IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2 V617F

Nanna Sulai, Thitina Jimma, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Ryan A Knudson, Rebecca F McClure, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 1751.

https://doi.org/10.1182/blood.V118.21.1751.1751

Published: 2011

Journal Articles

A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia

Kebede Begna, MD, Ruben A. Mesa, MD, Animesh Pardanani, MBBS, PhD, William J Hogan, MBBCh, Mark R. Litzow, MD, Rebecca F McClure, MD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4109.

https://doi.org/10.1182/blood.V116.21.4109.4109

Published: 2010

Journal Articles

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults

Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy M. Finke, Rebecca F. McClure, Chin-yang Li, Ayalew Tefferi

Blood (2010) 115 (1): 150–151.

https://doi.org/10.1182/blood-2009-10-249979

Published: 2010

Journal Articles

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin-Yang Li, Ayalew Tefferi

Blood (2009) 114 (18): 3769–3772.

https://doi.org/10.1182/blood-2009-05-220145

Published: 2009

Includes: Supplemental data

Journal Articles

Chronic myeloid leukemia with p190 BCR-ABL : prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

Animesh Pardanani, Ayalew Tefferi, Mark R. Litzow, Clive Zent, William J. Hogan, Rebecca F. McClure, David Viswanatha

Blood (2009) 114 (16): 3502–3503.

https://doi.org/10.1182/blood-2009-07-234666

Published: 2009

Journal Articles

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

Ken-Hong Lim, Ayalew Tefferi, Terra L. Lasho, Christy Finke, Mrinal Patnaik, Joseph H. Butterfield, Rebecca F. McClure, Chin-Yang Li, Animesh Pardanani

Blood (2009) 113 (23): 5727–5736.

https://doi.org/10.1182/blood-2009-02-205237

Published: 2009

Journal Articles

Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.

Ayalew Tefferi, MD, Naseema Gangat, MD, Alexandra P. Wolanskyj, MD, Susan M. Schwager, Animesh Pardanani, MD, PhD, Ruben A. Mesa, MD, Rebecca F. McClure, MD, Chin-Yang Li, MD, Curtis A. Hanson, MD

Blood (2007) 110 (11): 3546.

https://doi.org/10.1182/blood.V110.11.3546.3546

Published: 2007

Journal Articles

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Naseema Gangat, MBBS, Alexandra Wolanskyj, MD, Rebecca F. McClure, MD, Chin Y. Li, MD, Susan M. Schwager, Wenting Wu, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 3599.

https://doi.org/10.1182/blood.V108.11.3599.3599

Published: 2006

Journal Articles

MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

Animesh D. Pardanani, Ross L. Levine, Terra Lasho, Yana Pikman, Ruben A. Mesa, Martha Wadleigh, David P. Steensma, Michelle A. Elliott, Alexandra P. Wolanskyj, William J. Hogan, Rebecca F. McClure, Mark R. Litzow, D. Gary Gilliland, Ayalew Tefferi

Blood (2006) 108 (10): 3472–3476.

https://doi.org/10.1182/blood-2006-04-018879

Published: 2006

Journal Articles

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, Jorge Cortes, Srdan Verstovsek, Ruben A. Mesa, Deborah Thomas, Terra L. Lasho, William J. Hogan, Mark R. Litzow, Jacob B. Allred, Dan Jones, Catriona Byrne, Jerome B. Zeldis, Rhett P. Ketterling, Rebecca F. McClure, Francis Giles, Hagop M. Kantarjian

Blood (2006) 108 (4): 1158–1164.

https://doi.org/10.1182/blood-2006-02-004572

Published: 2006

Journal Articles

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

Natalia Gonzalez-Paz, Wee J. Chng, Rebecca F. McClure, Emily Blood, Martin M. Oken, Brian Van Ness, C. David James, Paul J. Kurtin, Kimberly Henderson, Gregory J. Ahmann, Morie Gertz, Martha Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Blood (2006) 109 (3): 1228–1232.

https://doi.org/10.1182/blood-2006-05-024661

Published: 2006

Journal Articles

JAK2 V617F Mutation in Essential Thrombocythemia: Clinical Associations and Long-Term Prognostic Relevance.

Alexandra P. Wolanskyj, MD, Terra L. Lasho, MT, ASCP, Susan M. Schwager, Rebecca F. McClure, MD, Martha Wadleigh, MD, Stephanie J. Lee, MD, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 254.

https://doi.org/10.1182/blood.V106.11.254.254

Published: 2005

Journal Articles

Lenalidomide (CC-5013) Treatment for Anemia Associated with Myelofibrosis with Myeloid Metaplasia.

Ayalew Tefferi, MD, Ruben A. Mesa, MD, William J. Hogan, MD, Trudy A. Shaw, Gayle E. Reyes, Jacob B. Allred, Cynthia X. Ma, MD, Grace K. Dy, MD, Alexandra P. Wolanskyj, MD, Mark L. Litzow, MD, David P. Steensma, MD, Timothy G. Call, MD, Rebecca F. McClure, MD

Blood (2005) 106 (11): 2583.

https://doi.org/10.1182/blood.V106.11.2583.2583

Published: 2005

Journal Articles

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

David P. Steensma, Gordon W. Dewald, Terra L. Lasho, Heather L. Powell, Rebecca F. McClure, Ross L. Levine, D. Gary Gilliland, Ayalew Tefferi

Blood (2005) 106 (4): 1207–1209.

https://doi.org/10.1182/blood-2005-03-1183

Published: 2005

Journal Articles

A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.

Ayalew Tefferi, MD, William J. Hogan, MD, Alexandra P. Wolanskyj, MD, Trudy A. Shaw, Gayle E. Reyes, Antje Hoering, PhD, Rebecca F. McClure, MD, Ruben A. Mesa, MD

Blood (2004) 104 (11): 1505.

https://doi.org/10.1182/blood.V104.11.1505.1505

Published: 2004

NARROW

Practical Acute Myeloid Leukemia (AML) Biomarker Testing Using Next-Generation Sequencing (NGS) Technology: A Comprehensive, Rapid, Inexpensive and Flexible Approach

IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2 V617F

A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

Chronic myeloid leukemia with p190 BCR-ABL : prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

JAK2 V617F Mutation in Essential Thrombocythemia: Clinical Associations and Long-Term Prognostic Relevance.

Lenalidomide (CC-5013) Treatment for Anemia Associated with Myelofibrosis with Myeloid Metaplasia.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only